Isosceles Pharmaceuticals
[Closed for Investment] Isosceles Pharmaceuticals, with a valuation of $30.8 million, is raising funds on Equifund CFP. It is a pharmaceutical company currently developing intravenous formulations of synthetic Cannabidiol as non-addictive alternatives to opium-based painkillers. The CBD formulations will be used for acute post-operative pain and will address the surgical population in the US, Europe, and the UK. Isosceles Pharmaceuticals is currently in the pre-clinical trials stage. Brett Lanier founded Isosceles Pharmaceuticals in April 2019. The current crowdfunding campaign has a minimum target of $20,000 and a maximum target of $5 million. The campaign proceeds will be used to fund pre-clinical animal trials and IND filings for a new intravenous drug delivery system.
Investment Overview
Raised: $5,000,000
Deal Terms
Total Commitments ($USD)
- Platform
- Equifund
- Start Date
- 10/04/2022
- Close Date
- 04/30/2023
$20,000
$5,000,000
$500
Equity - Common
Seed
RegCF
$2.05
$30,800,000
Company & Team
Company
- Year Founded
- 2019
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $750,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/30/2023 | Equifund | $30,800,000 | $5,000,000 | Equity - Common | Funded | RegCF |